$3.24
1.22%
Nasdaq, Sep 02, 10:11 pm CET
ISIN
US77313F1066
Symbol
RCKT

Rocket Pharmaceuticals, Inc. Stock price

$3.24
+0.17 5.54% 1M
-5.55 63.14% 6M
-9.33 74.22% YTD
-15.61 82.81% 1Y
-12.30 79.15% 3Y
-21.54 86.92% 5Y
-52.64 94.20% 10Y
-20.76 86.50% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.04 1.22%
ISIN
US77313F1066
Symbol
RCKT
Industry

Key metrics

Basic
Market capitalization
$349.6m
Enterprise Value
$99.1m
Net debt
positive
Cash
$271.5m
Shares outstanding
108.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 25.5
EV/Sales
- | 7.2
EV/FCF
negative
P/B
1.0
Financial Health
Equity Ratio
87.7%
Return on Equity
-55.9%
ROCE
-69.7%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $13.7m
EBITDA
$-253.2m | $-240.7m
EBIT
$-263.5m | $-247.8m
Net Income
$-257.0m | $-229.8m
Free Cash Flow
$-206.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
3.3% | 8.7%
EBIT
2.4% | 9.2%
Net Income
-1.3% | 11.3%
Free Cash Flow
2.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -1,753.9%
EBIT
-
Net
- | -1,674.5%
Free Cash Flow
-
More
EPS
$-2.3
FCF per Share
$-1.9
Short interest
21.2%
Employees
299
Rev per Employee
$0.0
Show more

Is Rocket Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Rocket Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Rocket Pharmaceuticals, Inc. forecast:

14x Buy
58%
9x Hold
38%
1x Sell
4%

Analyst Opinions

24 Analysts have issued a Rocket Pharmaceuticals, Inc. forecast:

Buy
58%
Hold
38%
Sell
4%

Financial data from Rocket Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 105 105
20% 20%
-
- Research and Development Expense 158 158
12% 12%
-
-253 -253
3% 3%
-
- Depreciation and Amortization 10 10
24% 24%
-
EBIT (Operating Income) EBIT -264 -264
2% 2%
-
Net Profit -257 -257
1% 1%
-

In millions USD.

Don't miss a Thing! We will send you all news about Rocket Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rocket Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
6 days ago
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 2025 Cantor Fitzgerald Global Healthcare Conference and the Morgan Stanley 23rd Annual Global Healthcare Conferenc...
Negative
Barrons
14 days ago
The past year has been a disappointing one for gene therapies.
Positive
Reuters
14 days ago
Rocket Pharmaceuticals said on Wednesday that the U.S. Food and Drug Administration has lifted the clinical hold on its gene therapy mid-stage trial.
More Rocket Pharmaceuticals, Inc. News

Company Profile

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.

Head office United States
CEO Gaurav Shah
Employees 299
Founded 1999
Website www.rocketpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today